- Home
- IMMX
IMMX
Immix Biopharma Inc.
as 12-26-2024 3:38pm EST
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | LOS ANGELES |
| Market Cap: | 61.1M | IPO Year: | 2021 |
| Target Price: | $7.00 | AVG Volume (30 days): | 258.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $7.46 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 200.00% |
Latest Immix Biopharma Inc. News
IMMX Breaking Stock News: Dive into IMMX Ticker-Specific Updates for Smart Investing
MT Newswires
7 days ago
Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis
GlobeNewswire
7 days ago
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
GlobeNewswire
10 days ago
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
MT Newswires
16 days ago
Immix Biopharma Gives Update on Clinical Data for Rare Disease Drug Candidate; Shares Lower
GlobeNewswire
16 days ago
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
Simply Wall St.
16 days ago
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
GlobeNewswire
17 days ago
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
GlobeNewswire
a month ago
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
Compare IMMX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMMX Immix Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.